Adverse event reporting in cancer clinical trial publications.
about
Adverse Event Recording and Reporting in Clinical Trials Comparing Lumbar Disk Replacement with Lumbar Fusion: A Systematic ReviewRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score.Ongoing challenges in pharmacovigilance.Emerging therapies for the prevention and treatment of oral mucositis.Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rashUse and misuse of common terminology criteria for adverse events in cancer clinical trials.Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254The use of and adherence to CTCAE v3.0 in cancer clinical trial publications.How to report toxicity associated with targeted therapies?Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future.The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.Benefit-Risk Analysis for Decision-Making: An Approach.Can urologists introduce the concept of "oligometastasis" for metastatic bladder cancer after total cystectomy?A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.Serious adverse events of older adults in nursing home and community intervention trials.A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.Adverse event reporting in oncology clinical trials - lost in translation?Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
P2860
Q26774858-D29FC3BC-A11C-453E-9A70-C642251537B8Q30241189-8408FF7F-2690-4064-95BE-1246AAEB576AQ33416289-A0F5F85A-8A42-4159-B730-1002AA8280E6Q34417013-FD18D7F5-2D98-4C33-B54B-B6E8B24BE1B3Q34432808-887E7A86-079D-402C-8BCF-992D7F1E095CQ35744647-458385BE-FAF3-40B1-BF2B-49D85D9AB17EQ35955607-B88F46B9-235F-4568-BEBF-1C4F3BFCABC3Q36052316-92E388A9-AEC3-40E7-81A5-73573E3E7737Q36067717-D8DB8EFA-D271-48DB-BCF7-8D1E5215A8C2Q36761020-09D37162-5788-4141-95C5-EED76352A24BQ36915159-4A4CB1B5-2138-4B5C-A8E5-F9B66014FC0FQ37011791-4C61FFB6-0BC0-45D7-84CA-8969D3251351Q37662274-303B76A9-CE4B-4EFC-BC86-80B9BAB0316DQ39741239-405C2CBA-8B70-441B-8114-8B9C2EFEADD0Q44267078-A7BF6742-6781-48B7-8150-419A4D533C0CQ47155450-55B2351A-98AE-43B4-ADFF-42FC79AC26B9Q47571376-3F9FBCE6-11C2-4FB5-826A-24556909E464Q47609603-E70864C7-4979-49CE-9D1B-DB3F2AA65E62Q47626358-037ED727-013E-4E36-ABB8-818DE0814633Q47919255-0577F65D-21A3-40CE-B42C-89025092B690Q47987968-ADCDFDCE-FB6A-4F73-98FA-2114C83167E1Q48770147-7E65AB9D-492B-46AB-84AB-248AD72A170FQ49235556-EE866838-5120-4D3F-A308-F99549D1869CQ50122392-F6D0904D-474B-4F65-AB1A-A97241ABD6FEQ52562488-AD07F212-9492-4B11-988E-ADC480EA5EBBQ52772305-69C7696C-7D89-404C-9838-91E587B9F4FAQ53001245-21533532-E5D3-4068-83DD-956CA11B5EDBQ53487785-76BFD7BC-7172-4740-9142-D8DCBFBBC236Q54189521-457CF583-50B5-49FE-8ECF-9908C35E8AF5Q57810588-143EE38D-CD70-43CC-B918-69ABA01E579B
P2860
Adverse event reporting in cancer clinical trial publications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adverse event reporting in cancer clinical trial publications.
@en
type
label
Adverse event reporting in cancer clinical trial publications.
@en
prefLabel
Adverse event reporting in cancer clinical trial publications.
@en
P2093
P356
P1476
Adverse event reporting in cancer clinical trial publications.
@en
P2093
Asma Latif
Kristian D Stensland
Lindsay Haines
Matthew D Galsky
Russell B McBride
Shanthi Sivendran
William K Oh
P356
10.1200/JCO.2013.52.2219
P407
P577
2013-12-09T00:00:00Z